CODEXIS, INC. (NASDAQ:CDXS) Files An 8-K Other Events
Item 8.01. Other Events.

On April5, 2018, Codexis, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Cowen and Company, LLC as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), to which the Company agreed to issue and sell 3,750,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), to the Underwriters (the “Offering”). The Shares were sold at a public offering price of $9.25 per Share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters the right, for 30 days, to purchase up to 562,500 additional shares of Common Stock. On April6, 2018, the Underwriters exercised their right to purchase the additional 562,500 shares of Common Stock in full.

The Offering was made under a prospectus supplement and related prospectus filed with the Securities and Exchange Commission to the Company’s effective shelf registration statement on Form S-3 (Registration No.333-215025).

to the Underwriting Agreement, the Company agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the Underwriters may be required to make because of such liabilities. The Company and all of the Company’s directors and executive officers also agreed not to sell or transfer any Common Stock held by them for 90 days after April5, 2018 without first obtaining the written consent of the Representatives on behalf of the Underwriters, subject to certain exceptions as described in the prospectus supplement.

On April10, 2018, the Offering closed and the Company completed the sale and issuance of an aggregate of 4,312,500 shares of Common Stock. The Company received net proceeds from the Offering of approximately $37.2million, after deducting the Underwriters’ discounts and commissions and estimated offering expenses payable by the Company.

A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement and lock-up arrangements do not purport to be complete and are qualified in their entirety by reference to such exhibit.

A copy of the opinion of Latham& Watkins LLP relating to the validity of the securities issued in the Offering is filed herewith as Exhibit 5.1.

Item 8.01. Financial Statements and Exhibits.

(d)Exhibits.

CODEXIS INC Exhibit
EX-1.1 2 d456589dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 EXECUTION VERSION 3,…
To view the full exhibit click here

About CODEXIS, INC. (NASDAQ:CDXS)

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

CODEXIS, INC. (NASDAQ:CDXS) Recent Trading Information

CODEXIS, INC. (NASDAQ:CDXS) closed its last trading session up +0.77 at 11.65 with shares trading hands.